StockNews.AI
ARDX
StockNews.AI
201 days

Ardelyx to Report Full Year and Fourth Quarter 2024 Financial Results on February 20, 2025

1. Ardelyx will hold a conference call on February 20, 2025. 2. The call will discuss financial results for Q4 and full year 2024. 3. Ardelyx's commercial products include IBSRELA and XPHOZAH, addressing unmet needs. 4. A New Drug Application for tenapanor has been submitted for China market. 5. Tenapanor is commercialized in Japan and Canada through partnerships.

4m saved
Insight
Article

FAQ

Why Bullish?

The upcoming conference call may reveal strong financial performance and future growth prospects.

How important is it?

The conference call could significantly influence investor perception and stock price recovery.

Why Short Term?

Market reactions are likely immediate based on the call's findings and updates.

Related Companies

IBSRXPHOZ
Conference call scheduled for 8:00 a.m. Eastern Time January 30, 2025 16:30 ET  | Source: Ardelyx, Inc. WALTHAM, Mass., Jan. 30, 2025 (GLOBE NEWSWIRE) -- Ardelyx, Inc. (Nasdaq: ARDX), a biopharmaceutical company founded with a mission to discover, develop and commercialize innovative, first-in-class medicines that meet significant unmet medical needs, today announced it will hold a conference call on Thursday, February 20, 2025, at 8:00 a.m. Eastern Time to discuss financial results and provide a business update from the full year and fourth quarter of 2024. To participate in the conference call, please dial (877) 346-6112 (domestic) or (848) 280-6350 (international) and ask to be joined into the Ardelyx call. Live audio of the conference call will be simultaneously webcast and will be available under the Investors section of the company's website at www.ardelyx.com. The webcast will be archived and available for replay for 30 days following the call. About ArdelyxArdelyx was founded with a mission to discover, develop and commercialize innovative, first-in-class medicines that meet significant unmet medical needs. Ardelyx has two commercial products approved in the United States, IBSRELA® (tenapanor) and XPHOZAH® (tenapanor). Ardelyx has agreements for the development and commercialization of tenapanor outside of the U.S. Kyowa Kirin commercializes PHOZEVEL® (tenapanor) for hyperphosphatemia in Japan. A New Drug Application for tenapanor for hyperphosphatemia has been submitted in China with Fosun Pharma. Knight Therapeutics commercializes IBSRELA in Canada. For more information, please visit https://ardelyx.com/ and connect with us on X (formerly known as Twitter), LinkedIn and Facebook. Investor and Media Contacts: Caitlin Lowieclowie@ardelyx.com

Related News